Table 1.
Clinical characteristics of the study participants
| Vonoprazan group n = 85 |
Lansoprazole group n = 83 |
P value | |
|---|---|---|---|
| Age (years), median (range) | 73 (47–89) | 73 (33–90) | 0.96 |
| Sex, male, n (%) | 63 (74) | 58 (70) | 0.54 |
| Habits | |||
| Smoking, n (%) | 16 (19) | 16 (19) | 0.94 |
| Alcohol, n (%) | 36 (42) | 34 (41) | 0.86 |
| Anti-Helicobacter pylori IgG antibody | |||
| Positive, n (%) | 30 (35) | 31 (37) | 0.78 |
| *PPI use prior to treatment | |||
| Yes, n (%) | 24 (28) | 18 (22) | 0.33 |
| Comorbidities | |||
| Hypertension, n (%) | 56 (66) | 44 (53) | 0.089 |
| Diabetes mellitus, n (%) | 18 (21) | 14 (17) | 0.48 |
| Ischemic heart disease, n (%) | 0 (0) | 2 (2) | 0.24 |
| Cerebral infarction, n (%) | 0 (0) | 1 (1) | 0.49 |
| Location of lesion | |||
| Upper third, n (%) | 9 (11) | 11 (13) | 0.28 |
| Middle third, n (%) | 35 (41) | 42 (51) | |
| Lower third, n (%) | 41 (48) | 30 (36) | |
| Lesion size (mm), median (range) | 10 (2–54) | 10 (2–40) | 0.85 |
| Preoperative histological diagnosis | |||
| Adenoma, n (%) | 19 (22) | 27 (32) | 0.20 |
| Differentiated adenocarcinoma, n (%) | 64 (75) | 52 (63) | |
| Undifferentiated adenocarcinoma, n (%) | 2 (2) | 2 (2) | |
| Neuroendocrine tumor grade 1, n (%) | 0 (0) | 2 (2) | |
| Ulcer scar in tumor, n (%) | 6 (7) | 7 (8) | 0.74 |
| †ESD ulcer index (mm2), median (range) | 875 (260–4000) | 875 (238–4180) | 0.59 |
*PPI, proton pump inhibitor; †ESD, endoscopic submucosal dissection